🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

FDA grants accelerated approval to Enhertu for metastatic HER2-positive cancers

EditorAhmed Abdulazez Abdulkadir
Published 04/06/2024, 08:58 AM
© Reuters.

WASHINGTON D.C. - The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Enhertu for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment and lack satisfactory alternative options.

Enhertu is an antibody drug conjugate (ADC) specifically engineered to target HER2-positive tumors and is co-developed by AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo.

The approval, announced today, marks the first time a tumor-agnostic HER2-directed therapy has been authorized by the FDA. The decision is based on objective response rate (ORR) and duration of response (DoR) observed in patients across three Phase II trials: DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02.

Dr. Funda Meric-Bernstam of The University of Texas MD Anderson Cancer Center highlighted the limited treatment options previously available for patients with metastatic HER2-positive solid tumors and noted the clinically meaningful response rates seen across clinical trials.

Dave Fredrickson from AstraZeneca emphasized the significance of this milestone, stating that Enhertu's approval underscores the importance of biomarker testing across various tumors to identify patients who may benefit from targeted therapies. Ken Keller of Daiichi Sankyo echoed the sentiment, referencing the clinically meaningful efficacy of Enhertu across different metastatic cancers.

The safety profile of Enhertu was consistent with previous clinical trials, evaluated in 347 patients with unresectable or metastatic HER2-positive solid tumors. The FDA's accelerated approval is contingent upon the verification and description of clinical benefit in a confirmatory trial.

Furthermore, Enhertu has been included in the NCCN Clinical Practice Guidelines in Oncology as a treatment option for multiple metastatic tumors. The FDA reviewed the US regulatory submission under Project Orbis, allowing for concurrent submission and review among international partners. Enhertu is also under review for the same indication in Australia, Brazil, and Singapore.

Sales of Enhertu in the US are recognized by Daiichi Sankyo, with AstraZeneca reporting its share of gross profit margin from US sales as alliance revenue in its financial statements.

This approval is a significant step for patients with metastatic HER2-positive solid tumors, offering a new therapeutic option where limited treatments were previously available. The information for this article is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.